PEA

Suspected endocannabinoid.

OEA

Suspected endocannabinoid.

2AGE/Noladin

Suspected cannabinoid that binds to several cannabinoid receptors.

Anandamide

Anandamide was the first identified endocannabinoid, named after the Sanskrit 'ananda' for inner bliss. Anandamide is produced from lipids in cellular membranes throughout the body.

Pain

pain is a very good target for therapeutic cannabinoids.

Alzheimer's disease

Alzheimer’s disease is a chronic neurodegenerative disease and the main cause of dementia. Main common symptoms of dementia are related with memory but other cognitive processes are affected during the development of the disease.

NADA

Suspected endocannabinoid.

Huntington's

Huntington's disease is a genetic neurodegenerative disorder, marked by preferential degeneration of neurons in the basal ganglia (caudate and putamen) and accompanied by motor deficits, cognitive impairment and psychiatric symptoms. There is considerable evidence for the involvement of the endocannabinoid system in Huntington's but clinical trials so far have been inconclusive.

Eczema

Eczema or dermatitis is a (chronic) inflammation of the skin. Eczema is marked by itchy skin and crusty skin lesions. It is not known what exactly causes Eczema but an over-active immune system may at least be part of the cause.

Bulimia

cannabinoids and endocannabinoids are known to strongly affect eating behavior. THC typically induces hunger and THCV suppresses it.